<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04728061</url>
  </required_header>
  <id_info>
    <org_study_id>GEn1E-1124-001</org_study_id>
    <nct_id>NCT04728061</nct_id>
  </id_info>
  <brief_title>Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of GEn1E-1124</brief_title>
  <official_title>A Phase 1a/1b, Randomized, Double-blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of GEn1E-1124 After Single and Multiple IV Infusion Dosing in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GEn1E Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GEn1E Lifesciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this early phase clinical research study, the investigational drug will be administered to&#xD;
      64 healthy volunteers in a double-blind, placebo-controlled manner, at a one research center.&#xD;
      The objectives of the study are to assess what the body does to the investigational drug,&#xD;
      what the investigational drug does to the body and also to observe the safety and&#xD;
      tolerability of the investigational drug healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 7, 2021</start_date>
  <completion_date type="Actual">June 18, 2021</completion_date>
  <primary_completion_date type="Actual">June 18, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of adverse events from the start of randomization through the final follow-up visit</measure>
    <time_frame>Up to 14 days post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of GEn1E-1124 and potential metabolites</measure>
    <time_frame>Through 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine levels of GEn1E-1124 and potential metabolites</measure>
    <time_frame>Through 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokines measured in whole blood</measure>
    <time_frame>Up to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Selected biomarkers measured in whole blood</measure>
    <time_frame>Up to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Single Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gen1E-1124</intervention_name>
    <description>Intravenously-infused Gen1E-1124 in vehicle.</description>
    <arm_group_label>Multiple Ascending Dose</arm_group_label>
    <arm_group_label>Single Ascending Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenously-infused vehicle.</description>
    <arm_group_label>Multiple Ascending Dose</arm_group_label>
    <arm_group_label>Single Ascending Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male and female subjects;&#xD;
&#xD;
          2. Between 18 and 55 years of age;&#xD;
&#xD;
          3. Provide a signed EC-approved consent form;&#xD;
&#xD;
          4. Generally healthy, in the opinion of the Investigator;&#xD;
&#xD;
          5. Body Mass Index (BMI) 18 to 30 kg/m^2;&#xD;
&#xD;
          6. Creatinine clearance with in specific parameter;&#xD;
&#xD;
          7. Using method of contraception;&#xD;
&#xD;
          8. Willing and able to comply with protocol requirements for the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects taking prohibited medication;&#xD;
&#xD;
          2. Subjects with a history or presence of clinically significant medical or psychiatric&#xD;
             disease;&#xD;
&#xD;
          3. Subjects who have regularly used nicotine-containing products ;&#xD;
&#xD;
          4. Subjects who have used caffeine-containing products;&#xD;
&#xD;
          5. Subjects who are unable to comply with eating a standardized meal during the study;&#xD;
&#xD;
          6. Subjects with a hospital admission or major surgery within 30 days prior to Screening;&#xD;
&#xD;
          7. Subjects with a plasma donation within 7 days prior to Screening;&#xD;
&#xD;
          8. Subjects who have not abstained from alcoholic beverages/alcohol-containing products&#xD;
             at least 72 hours prior to first dose, or plan to consume them at any time through&#xD;
             completion of the Follow-up Visit;&#xD;
&#xD;
          9. Subjects who cannot refrain from strenuous exercise from 72 hours prior to dose&#xD;
             administration through completion of the Follow-up Visit;&#xD;
&#xD;
         10. Subjects who are pregnant or breastfeeding&#xD;
&#xD;
         11. Subjects who have participated (taken investigative drug and/or device) in another&#xD;
             clinical trial within 90 days prior to Screening;&#xD;
&#xD;
         12. Subjects who are employees of the study unit or their family members, students who are&#xD;
             working in the study unit, or family members of the Investigator or Sponsor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ritu Lal, PhD, MS</last_name>
    <role>Study Director</role>
    <affiliation>GEn1E Lifesciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GEn1E-1124 Clinical Research Site</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <link>
    <url>https://www.gen1elifesci.com/</url>
    <description>Sponsor Website</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 22, 2021</study_first_submitted>
  <study_first_submitted_qc>January 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

